Evolution and immediate future of US screening guidelines

Kirsten L. Greene, Sanoj Punnen, Peter R. Carroll

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalUrologic Clinics of North America
Volume41
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Early Detection of Cancer
Uncertainty
Observational Studies
Prostatic Neoplasms
Clinical Trials
Guidelines
Safety
Light
Medical Overuse

Keywords

  • Guidelines
  • Prostate cancer
  • Prostate specific antigen (PSA)
  • Public health
  • Screening

ASJC Scopus subject areas

  • Urology

Cite this

Evolution and immediate future of US screening guidelines. / Greene, Kirsten L.; Punnen, Sanoj; Carroll, Peter R.

In: Urologic Clinics of North America, Vol. 41, No. 2, 2014, p. 229-235.

Research output: Contribution to journalArticle

Greene, Kirsten L. ; Punnen, Sanoj ; Carroll, Peter R. / Evolution and immediate future of US screening guidelines. In: Urologic Clinics of North America. 2014 ; Vol. 41, No. 2. pp. 229-235.
@article{c2927b32b6ba43db8a1f70e8b6ffcb1f,
title = "Evolution and immediate future of US screening guidelines",
abstract = "Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.",
keywords = "Guidelines, Prostate cancer, Prostate specific antigen (PSA), Public health, Screening",
author = "Greene, {Kirsten L.} and Sanoj Punnen and Carroll, {Peter R.}",
year = "2014",
doi = "10.1016/j.ucl.2014.01.005",
language = "English (US)",
volume = "41",
pages = "229--235",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Evolution and immediate future of US screening guidelines

AU - Greene, Kirsten L.

AU - Punnen, Sanoj

AU - Carroll, Peter R.

PY - 2014

Y1 - 2014

N2 - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

AB - Although observational studies and simulation models have shed some interesting light on many of the uncertainties surrounding prostate cancer screening, well-done clinical trials provide the best evidence on screening among the extremes of age, the most appropriate interval to screen, and the best complement of tests to use. Enthusiasm for screening is temporized by the acknowledgment that overdetection leads to frequent overtreatment despite evidence supporting the safety of active surveillance in many men with low-risk disease.

KW - Guidelines

KW - Prostate cancer

KW - Prostate specific antigen (PSA)

KW - Public health

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84898029953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898029953&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2014.01.005

DO - 10.1016/j.ucl.2014.01.005

M3 - Article

C2 - 24725485

AN - SCOPUS:84898029953

VL - 41

SP - 229

EP - 235

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 2

ER -